Denali Therapeutics Inc. (DNLI) income statement
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.45+0.25 (+1.37%)
Close on Nov 20, 2026Market cap $2.95BP/E –Yield –
Denali Therapeutics Inc. financial ratios
See a number that looks wrong?